Fundraising Fox

Centrexion

Baltimore, US · Founded 2013 · 3 known investors

centrexion.com ↗

Centrexion is a pharmaceutical company developing drugs in two therapeutic areas: non-opioid pain relief and immunology. It works with partners such as Lilly, Boehringer Ingelheim, and NIH to build a portfolio addressing high unmet medical needs.

Biotechin /10487363@CentrexionTX

Founders & leadership

SB
Sol BarerDirector
KL
Kerrie L. BradyExecutive Officer
JN
James N. CampbellExecutive Officer, Director
SZ
Shengda ZanDirector
GB
Gregg BeloffExecutive Officer
AL
Arnold L. OronskyDirector
IB
Isaac BlechDirector
JB
Jeffrey B. KindlerExecutive Officer

Investors · 3

Catalio Capital Management, LPNew York
EFung CapitalShenzhen
Quan CapitalShanghai

Reported raises · per SEC filings

Form D private placements
▶$3.3MraisedJan 2024 · 116 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shawn TomaselloDirector
  • Michael J. WardExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
  • Sol Barer, Ph.D.Director
  • Colin HillDirector
  • Randall M. StevensExecutive Officer
  • Joseph R. SwedishDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • J.C. Lopez, M.D.Director
Offering amount
$12.9M
Amount sold
$3.3M
Sales commissions
$1.3M
Placement agents
Maxim Group LLC
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael J. WardExecutive Officer
  • Shawn TomaselloDirector
  • Sol Barer, Ph.D.Director
  • Colin HillDirector
  • J.C. Lopez, M.D.Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Joseph R. SwedishDirector
  • Randall M. StevensExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
Offering amount
$2.3M
Amount sold
$2.3M
Sales commissions
$230K
Placement agents
FCC Ltd., Maxim Group LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.3MraisedJul 2023 · 124 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph R. SwedishDirector
  • Randall M. StevensExecutive Officer
  • Sol Barer, Ph.D.Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Colin HillDirector
  • Michael J. WardExecutive Officer
  • J.C. Lopez, M.D.Director
  • James N. Campbell, M.D.Executive Officer, Director
  • Shawn TomaselloDirector
Offering amount
$30M
Amount sold
$10.3M
Sales commissions
$3M
Placement agents
Maxim Group LLC
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.1MraisedAug 2022 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • J. C. Lopez, M.D.Director
  • Sol BarerDirector
  • Michael J. WardExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
  • Peter WirthDirector
  • Shawn TomaselloDirector
  • Randall M. StevensExecutive Officer
  • Joseph R. SwedishDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Colin HillDirector
  • Dezhi Kang, Ph.D.Director
Offering amount
$29.1M
Amount sold
$29.1M
Finders' fees
$2.6M
Placement agents
Maxim Group LLC
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedJan 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel MendelsonDirector
  • Sara NayeemDirector
  • Joseph R. SwedishDirector
  • Shawn TomaselloDirector
  • Stella XuDirector
  • James N. CampbellExecutive Officer, Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Sol BarerDirector
  • Randall M. StevensExecutive Officer
  • Michael J. WardExecutive Officer
Offering amount
$13.5M
Amount sold
$13.5M
Finders' fees
$945K
Placement agents
Maxim Group LLC
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$69.6MraisedJan 2018 · 67 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregg BeloffExecutive Officer
  • Sol J. BarerDirector
  • James N. CampbellExecutive Officer, Director
  • Arnold OronskyDirector
  • Sara NayeemDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Isaac BlechDirector
  • Randall M. StevensExecutive Officer
  • Shawn TomaselloDirector
Offering amount
$69.6M
Amount sold
$69.6M
Sales commissions
$3.6M
Placement agents
Maxim Group LLC, Leerink Partners LLC
First sale
Dec 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.3MraisedMay 2017 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James N. CampbellExecutive Officer, Director
  • Sol J. BarerDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Arnold OronskyDirector
  • Randall M. StevensExecutive Officer
Amount sold
$5.3M
Sales commissions
$212.4K
Placement agents
CIM Securities, LLC
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.6MraisedJan 2017 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kerrie L. BradyExecutive Officer
  • Sol BarerDirector
  • Shengda ZanDirector
  • Isaac BlechDirector
  • James N. CampbellExecutive Officer, Director
  • Jeffrey B. KindlerExecutive Officer
  • Arnold L. OronskyDirector
  • Gregg BeloffExecutive Officer
Offering amount
$16.6M
Amount sold
$16.6M
Minimum investment
$25K
Sales commissions
$1.3M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.